[Efficiency of ACE inhibitors, beta adrenoblocker and antihypoxant in the phase of stationary rehabilitation of patients with myocardial infarction working in environmentally unfriendly conditions].
The aim of this work was to study effect of fosinopril combined with propranolol or cytomack on ecoendotoxicosis, size of myocardial infarction (MI), left ventricular (LV) systolic function, and clinical picture of stationary phase MI in patients working in environmentally unfriendly conditions. 42 patients aged 30-70 yr presenting with MI and initial Q-wave were randomized into 2 groups of 21 subjects each. In group 1, they were given fosinopril with propranolol, in group 2 fosinopril with cytomack. Mean age of group 1 and 2 patients was 57.8 +/- 2.1 and 56.9 +/- 23 yr respectively. All the patients were hospitalized within 6 hr after onset of the disease and received heparin. They underwent PETG and echoCG, also studied were endotoxicosis (PSD), central hemodynamics, left ventricular systolic functions (ESV, EDV, EF), size of MI (total ST, AST, total Rh), and clynical symptoms. It was shown that patients working in environmentally unfriendly conditions were characterized by high degree of PSD. In group 1 they exhibited reduction of PSD, total ST, AST, ESV, EDV and increase of total Rh and EF. Decreased systolic and diastolic AP did not lead to clinically significant hypotension. Patients of group 2 showed stabilization of AP, decrease of PSD, total ST, AST, ESV, EDV and increase of total Rh and EF that prevented the development of cardiac insufficiency in the phase of stationary rehabilitation of MI. Characteristics of groups 1 and 2 were not significantly different. The clinical course of IM in patients given fosinopril with cytomack was more favourable than in those treated with fosinopril and propranolol. Two patients of group 1 suffered cardiac insufficiency.
Agaev
M M
MM
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D004781:Environmental Exposure / Q000009:adverse effects*; D018876:Environmental Illness / Q000150:complications* / Q000534:rehabilitation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000209:etiology / Q000503:physiopathology / Q000534:rehabilitation*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D014665:Vasodilator Agents